Clinical Scorecard: Semaglutide as an Adjunct Therapy in Patients Receiving Intragastric Balloon Treatment for Weight Loss: A 12-Month Prospective Comparative Analysis
At a Glance
Category
Detail
Condition
Obesity and overweight
Key Mechanisms
Intragastric balloon induces satiety via gastric space occupation; Semaglutide, a GLP-1 receptor agonist, promotes weight loss through appetite suppression and metabolic effects
Target Population
Adults aged 18-65 years with BMI ≥ 27 kg/m² undergoing intragastric balloon placement
Care Setting
Endoscopic bariatric therapy setting with outpatient follow-up
Key Highlights
Combination of intragastric balloon (IGB) and semaglutide may enhance weight loss efficacy compared to IGB alone
Semaglutide dosing was titrated from 0.5 mg to 1 mg weekly during balloon placement and reintroduced after balloon removal
Study included structured dietary counseling and lifestyle modification support alongside interventions
Guideline-Based Recommendations
Diagnosis
Identify obesity based on BMI ≥ 27 kg/m² with or without weight-related comorbidities
Exclude patients with contraindications to IGB or semaglutide such as prior bariatric surgery, gastrointestinal disorders, severe organ dysfunction, pregnancy, or concurrent anti-obesity medications
Management
Initiate treatment with lifestyle interventions including diet and physical activity
Consider endoscopic bariatric therapy with intragastric balloon for patients reluctant to undergo surgery
Use semaglutide as adjunct pharmacotherapy in combination with IGB to potentially improve weight loss outcomes
Follow a semaglutide dosing schedule starting at 0.5 mg weekly, escalating to 1 mg weekly during balloon placement, pausing during latter balloon months, and reintroducing post-removal
Monitoring & Follow-up
Perform endoscopic placement and removal of IGB under conscious sedation by experienced endoscopists
Monitor patient adherence to dietary protocols and lifestyle modifications throughout treatment
Observe for adverse effects related to semaglutide and IGB during treatment phases
Risks
Potential adverse effects from IGB including gastrointestinal discomfort and procedural risks
Semaglutide-related side effects such as nausea, vomiting, or injection site reactions
Contraindications include inflammatory bowel disease, gastroparesis, severe organ dysfunction, pregnancy, and prior bariatric surgery
Patient & Prescribing Data
Adults with overweight or obesity (BMI ≥ 27 kg/m²) eligible for intragastric balloon therapy
Semaglutide administered subcutaneously once weekly with dose escalation to 1 mg may synergize with IGB to enhance weight loss; dosing paused during latter balloon months and resumed post-removal to maintain efficacy and tolerability
Clinical Best Practices
Ensure thorough patient screening and exclusion of contraindications prior to IGB and semaglutide therapy
Use a structured semaglutide titration schedule to minimize adverse effects
Provide continuous dietary counseling and lifestyle support alongside medical and endoscopic interventions
Maintain close follow-up to monitor treatment adherence and manage side effects
Employ experienced endoscopists for safe IGB placement and removal
